This company has been acquired
Epizyme (EPZM) Stock Overview
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
EPZM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Epizyme, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$5.80 |
| 52 Week Low | US$0.41 |
| Beta | -0.42 |
| 1 Month Change | -0.68% |
| 3 Month Change | 182.37% |
| 1 Year Change | -72.78% |
| 3 Year Change | -89.29% |
| 5 Year Change | -89.54% |
| Change since IPO | -93.61% |
Recent News & Updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16
Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Shareholder Returns
| EPZM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.3% | 3.6% | -0.4% |
| 1Y | -72.8% | 26.9% | 12.7% |
Return vs Industry: EPZM underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: EPZM underperformed the US Market which returned -11.7% over the past year.
Price Volatility
| EPZM volatility | |
|---|---|
| EPZM Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EPZM's share price has been volatile over the past 3 months.
Volatility Over Time: EPZM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 250 | Grant Bogle | www.epizyme.com |
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others.
Epizyme, Inc. Fundamentals Summary
| EPZM fundamental statistics | |
|---|---|
| Market cap | US$247.50m |
| Earnings (TTM) | -US$207.73m |
| Revenue (TTM) | US$53.01m |
Is EPZM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPZM income statement (TTM) | |
|---|---|
| Revenue | US$53.01m |
| Cost of Revenue | US$10.79m |
| Gross Profit | US$42.22m |
| Other Expenses | US$249.95m |
| Earnings | -US$207.73m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 79.64% |
| Net Profit Margin | -391.88% |
| Debt/Equity Ratio | -1,148.4% |
How did EPZM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/12 17:45 |
| End of Day Share Price | 2022/08/11 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Epizyme, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mohit Bansal | Citigroup Inc |
| Michael King | Citizens JMP Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |